The Filings Report

Charles River Laboratories International, Inc.

CRLNYSECIK 1100682Healthcare / Diagnostics & Researchfiscal year ends December69 quarters since 2009

Revenue, Q2 FY2026
$1.0B
−2.7% on Q2 FY2025
Net income
−$1M
−102.8% on Q2 FY2025
Free cash flow
$149M
−12.2% on Q2 FY2025
Diluted EPS
$-0.03
−102.8% on Q2 FY2025
Revenue, TTM
$4.0B
trailing four quarters
Net margin, TTM
-6.0%
net income −$238M
Free cash flow, TTM
$371M
$582M less $212M capex
Cash and equivalents
$192M
long-term debt —, Jun 27, 2026
Shares, 12-month change
−3.0%
48M shares, Jun 27, 2026
Buybacks, TTM
$324M
2.0% of market value
Dividends, TTM
—
no yield
Market value
$16.2B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 27, 2026, Charles River Laboratories International, Inc. reported revenue of $1.0B, −2.7% on Q2 FY2025, and net loss of $1M (−102.8%). Operating margin was 11.9%. Free cash flow, operating cash flow less capital expenditures, was $149M ($180M less $31M). Diluted earnings per share were $-0.03.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
−$500M$0$500M$1.0B$1.5BQ3'22, Revenue: $989MQ3'22, Net income: $96MQ3'22Q4'22, Revenue: $1.1BQ4'22, Net income: $187MQ4'22Q1'23, Revenue: $1.0BQ1'23, Net income: $103MQ1'23Q2'23, Revenue: $1.1BQ2'23, Net income: $97MQ2'23Q3'23, Revenue: $1.0BQ3'23, Net income: $87MQ3'23Q4'23, Revenue: $1.0BQ4'23, Net income: $187MQ4'23Q1'24, Revenue: $1.0BQ1'24Q2'24, Revenue: $1.0BQ2'24Q3'24, Revenue: $1.0BQ3'24, Net income: $70MQ3'24Q4'24, Revenue: $1.0BQ4'24, Net income: −$214MQ4'24Q1'25, Revenue: $984MQ1'25, Net income: $25MQ1'25Q2'25, Revenue: $1.0BQ2'25, Net income: $52MQ2'25Q3'25, Revenue: $1.0BQ3'25, Net income: $54MQ3'25Q4'25, Revenue: $994MQ4'25, Net income: −$277MQ4'25Q1'26, Revenue: $996MQ1'26, Net income: −$15MQ1'26Q2'26, Revenue: $1.0BQ2'26, Net income: −$1MQ2'26−$500M$0$500M$1.0B$1.5BQ3'22, Revenue: $989MQ3'22, Net income: $96MQ4'22, Revenue: $1.1BQ4'22, Net income: $187MQ4'22Q1'23, Revenue: $1.0BQ1'23, Net income: $103MQ2'23, Revenue: $1.1BQ2'23, Net income: $97MQ2'23Q3'23, Revenue: $1.0BQ3'23, Net income: $87MQ4'23, Revenue: $1.0BQ4'23, Net income: $187MQ4'23Q1'24, Revenue: $1.0BQ2'24, Revenue: $1.0BQ2'24Q3'24, Revenue: $1.0BQ3'24, Net income: $70MQ4'24, Revenue: $1.0BQ4'24, Net income: −$214MQ4'24Q1'25, Revenue: $984MQ1'25, Net income: $25MQ2'25, Revenue: $1.0BQ2'25, Net income: $52MQ2'25Q3'25, Revenue: $1.0BQ3'25, Net income: $54MQ4'25, Revenue: $994MQ4'25, Net income: −$277MQ4'25Q1'26, Revenue: $996MQ1'26, Net income: −$15MQ2'26, Revenue: $1.0BQ2'26, Net income: −$1MQ2'26

Net income losses drawn in red.

Free cash flow
−$100M$0$100M$200M$300MQ3'22, Free cash flow: $60MQ3'22Q4'22, Free cash flow: $146MQ4'22Q1'23, Free cash flow: $3MQ1'23Q2'23, Free cash flow: $81MQ2'23Q3'23, Free cash flow: $140MQ3'23Q4'23, Free cash flow: $143MQ4'23Q1'24, Free cash flow: $51MQ1'24Q2'24, Free cash flow: $154MQ2'24Q3'24, Free cash flow: $213MQ3'24Q4'24, Free cash flow: $84MQ4'24Q1'25, Free cash flow: $112MQ1'25Q2'25, Free cash flow: $169MQ2'25Q3'25, Free cash flow: $178MQ3'25Q4'25, Free cash flow: $59MQ4'25Q1'26, Free cash flow: −$15MQ1'26Q2'26, Free cash flow: $149MQ2'26−$100M$0$100M$200M$300MQ3'22, Free cash flow: $60MQ4'22, Free cash flow: $146MQ4'22Q1'23, Free cash flow: $3MQ2'23, Free cash flow: $81MQ2'23Q3'23, Free cash flow: $140MQ4'23, Free cash flow: $143MQ4'23Q1'24, Free cash flow: $51MQ2'24, Free cash flow: $154MQ2'24Q3'24, Free cash flow: $213MQ4'24, Free cash flow: $84MQ4'24Q1'25, Free cash flow: $112MQ2'25, Free cash flow: $169MQ2'25Q3'25, Free cash flow: $178MQ4'25, Free cash flow: $59MQ4'25Q1'26, Free cash flow: −$15MQ2'26, Free cash flow: $149MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$100M$200M$300M$400MQ3'22, Cash and equivalents: $194MQ3'22Q4'22, Cash and equivalents: $234MQ4'22Q1'23, Cash and equivalents: $202MQ1'23Q2'23, Cash and equivalents: $200MQ2'23Q3'23, Cash and equivalents: $157MQ3'23Q4'23, Cash and equivalents: $277MQ4'23Q1'24, Cash and equivalents: $327MQ1'24Q2'24, Cash and equivalents: $179MQ2'24Q3'24, Cash and equivalents: $210MQ3'24Q4'24, Cash and equivalents: $195MQ4'24Q1'25, Cash and equivalents: $229MQ1'25Q2'25, Cash and equivalents: $183MQ2'25Q3'25, Cash and equivalents: $207MQ3'25Q4'25, Cash and equivalents: $214MQ4'25Q1'26, Cash and equivalents: $192MQ1'26Q2'26, Cash and equivalents: $192MQ2'26$0$100M$200M$300M$400MQ3'22, Cash and equivalents: $194MQ4'22, Cash and equivalents: $234MQ4'22Q1'23, Cash and equivalents: $202MQ2'23, Cash and equivalents: $200MQ2'23Q3'23, Cash and equivalents: $157MQ4'23, Cash and equivalents: $277MQ4'23Q1'24, Cash and equivalents: $327MQ2'24, Cash and equivalents: $179MQ2'24Q3'24, Cash and equivalents: $210MQ4'24, Cash and equivalents: $195MQ4'24Q1'25, Cash and equivalents: $229MQ2'25, Cash and equivalents: $183MQ2'25Q3'25, Cash and equivalents: $207MQ4'25, Cash and equivalents: $214MQ4'25Q1'26, Cash and equivalents: $192MQ2'26, Cash and equivalents: $192MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Charles River Laboratories International, Inc. income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 27, 2026filed Aug 5, 2026Q1 FY2026ended Mar 28, 2026filed May 7, 2026Q4 FY2025ended Dec 27, 2025filed Feb 18, 2026Q3 FY2025ended Sep 27, 2025filed Nov 5, 2025Q2 FY2025ended Jun 28, 2025filed Aug 6, 2025Q1 FY2025ended Mar 29, 2025filed May 7, 2025Q4 FY2024ended Dec 28, 2024filed Feb 19, 2025Q3 FY2024ended Sep 28, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue1,0049969941,0051,0329841,0031,010−2.7%
Cost of revenue———————661—
Gross profit—————————
Research and development—————————
Selling, general and administrative229159196178192178196199+19.5%
Operating income120120(283)134——(168)117—
Other income (expense)(37)(124)12(23)0(12)(23)3−24392.2%
Pretax income—————————
Income tax54(15)(18)321910(3)21+188.0%
Net income(1)(15)(277)545225(214)70−102.8%
Diluted EPS ($)(0.03)(0.30)—1.101.060.50—1.33−102.8%
Diluted shares (millions)4849—494951—52—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Charles River Laboratories International, Inc. balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 27, 2026filed Aug 5, 2026Q1 FY2026ended Mar 28, 2026filed May 7, 2026Q4 FY2025ended Dec 27, 2025filed Feb 18, 2026Q3 FY2025ended Sep 27, 2025filed Nov 5, 2025Q2 FY2025ended Jun 28, 2025filed Aug 6, 2025Q1 FY2025ended Mar 29, 2025filed May 7, 2025Q4 FY2024ended Dec 28, 2024filed Feb 19, 2025Q3 FY2024ended Sep 28, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents192192214207183229195210+5.0%
Short-term investments—————————
Total current assets1,5291,4891,4471,5321,4701,5061,4031,495+4.0%
Total assets7,5327,7307,1357,5147,5617,5827,5288,004−0.4%
Total current liabilities1,1351,0941,1201,1221,0801,0519941,012+5.0%
Long-term debt—————————
Total liabilities4,6444,7423,9244,0634,1614,3414,0204,176+11.6%
Stockholders’ equity2,8402,9413,1653,4053,3533,1943,4623,782−15.3%
Shares outstanding (millions)4848494949495151—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Charles River Laboratories International, Inc. cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 27, 2026filed Aug 5, 2026Q1 FY2026ended Mar 28, 2026filed May 7, 2026Q4 FY2025ended Dec 27, 2025filed Feb 18, 2026Q3 FY2025ended Sep 27, 2025filed Nov 5, 2025Q2 FY2025ended Jun 28, 2025filed Aug 6, 2025Q1 FY2025ended Mar 29, 2025filed May 7, 2025Q4 FY2024ended Dec 28, 2024filed Feb 19, 2025Q3 FY2024ended Sep 28, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow18041148214205172159252−12.2%
Capital expenditures3156893635597639−11.9%
Free cash flow (CFO − capex)149(15)5917816911284213−12.2%
Depreciation and amortization6767788512012010288−43.7%
Share repurchases1162080073530101+1472.3%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 18, 2026.

Income statement

Charles River Laboratories International, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 27, 2025filed Feb 18, 2026FY2024ended Dec 28, 2024filed Feb 19, 2025FY2023ended Dec 30, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 25, 2021filed Feb 16, 2022FY2020ended Dec 26, 2020filed Feb 17, 2021FY2019ended Dec 28, 2019filed Feb 11, 2020FY2018ended Dec 29, 2018filed Feb 13, 2019FY2017ended Dec 30, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 26, 2015filed Feb 12, 2016FY2014ended Dec 27, 2014filed Feb 17, 2015FY2013ended Dec 28, 2013filed Feb 25, 2014FY2012ended Dec 29, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 25, 2010filed Feb 23, 2011FY2009ended Dec 26, 2009filed Aug 3, 2010FY2008ended Dec 27, 2008filed Aug 3, 2010
Revenue4,0154,0504,1293,9763,5402,9242,6212,2661,8581,6811,3631,2981,1661,1301,1431,1331,1721,295
Cost of revenue——————————————————
Gross profit——————————————————
Research and development——————————————————
Selling, general and administrative743751748665620529518444371365300269226208199232228224
Operating income25227617651590433351331288238206178151166174(299)170(452)
Other income (expense)(23)(17)9631(36)100121338123117(3)0(1)2(5)
Pretax income(100)93581623481447304282297223195178138130133(334)152(471)
Income tax43681011308282505417167434833281704057
Net income(144)22475486391364252226123155149127103——(337)114(525)
Diluted EPS ($)(2.91)0.209.229.487.607.205.074.622.543.233.132.662.122.012.14(5.38)1.74(7.80)
Diluted shares (millions)5052515151515049494848484848516366—

Balance sheet

Charles River Laboratories International, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 27, 2025filed Feb 18, 2026FY2024ended Dec 28, 2024filed Feb 19, 2025FY2023ended Dec 30, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 25, 2021filed Feb 16, 2022FY2020ended Dec 26, 2020filed Feb 17, 2021FY2019ended Dec 28, 2019filed Feb 11, 2020FY2018ended Dec 29, 2018filed Feb 13, 2019FY2017ended Dec 30, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 26, 2015filed Feb 12, 2016FY2014ended Dec 27, 2014filed Feb 17, 2015FY2013ended Dec 28, 2013filed Feb 25, 2014FY2012ended Dec 29, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 25, 2010filed Feb 23, 2011FY2009ended Dec 26, 2009filed Aug 3, 2010FY2008ended Dec 27, 2008filed Aug 3, 2010
Cash and equivalents21419527723424122823819516411811816015611069179183244
Short-term investments————111128421—117510——
Total current assets1,4471,4031,6091,4391,2741,2011,021898827657559579553485426553596—
Total assets7,1357,5288,1957,6037,0245,4914,6933,8562,9302,7122,0681,8711,6331,5861,5581,7332,204—
Total current liabilities1,1209941,0551,0921,033840710558464430312295247342217260250—
Long-term debt———————1,6271,0921,188821722642527703670——
Total liabilities3,9244,0204,5364,5794,4323,3473,0262,5181,8661,8581,3031,1669689831,0311,045830—
Stockholders’ equity3,1653,4623,5972,9762,5352,1151,6351,3171,0458377336726416015266871,375—
Shares outstanding (millions)49515151505049484747474748484956——

Cash flow statement

Charles River Laboratories International, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 27, 2025filed Feb 18, 2026FY2024ended Dec 28, 2024filed Feb 19, 2025FY2023ended Dec 30, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 25, 2021filed Feb 16, 2022FY2020ended Dec 26, 2020filed Feb 17, 2021FY2019ended Dec 28, 2019filed Feb 11, 2020FY2018ended Dec 29, 2018filed Feb 13, 2019FY2017ended Dec 30, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 26, 2015filed Feb 12, 2016FY2014ended Dec 27, 2014filed Feb 17, 2015FY2013ended Dec 28, 2013filed Feb 25, 2014FY2012ended Dec 29, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 25, 2010filed Feb 23, 2011FY2009ended Dec 26, 2009filed Aug 3, 2010FY2008ended Dec 27, 2008filed Aug 3, 2010
Operating cash flow738735684620761547481441318317————————
Capital expenditures219233319325229167141140825563573948494380199
Free cash flow (CFO − capex)518502365295532380340301236262————————
Depreciation and amortization4033623143042662351981621311279596978185949087
Share repurchases361119243941241814107121171221666428435746115
Dividends paid——————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$3K
1 purchases by 1 insider; officers and directors $3K
Sold, three months
$35M
20 sales by 6 insiders; officers and directors $35M
Bought, twelve months
$7K
2 purchases by 2 insiders; officers and directors $7K
Sold, twelve months
$52M
21 sales by 6 insiders; officers and directors $52M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 22, 2026Foster James CDirectoroption exercise24,042$244.41$6M55,638Oct 26, 2026
Oct 22, 2026Foster James CDirectoropen-market sale10b5-124,042$350.00$8M31,596Oct 26, 2026
Oct 21, 2026Parisotto Shannon MCEVP, Disc & Safety Assessmentoption exercise2,156$244.41$527K6,963Oct 23, 2026
Oct 21, 2026Parisotto Shannon MCEVP, Disc & Safety Assessmentopen-market sale10b5-12,156$344.41$743K4,807Oct 23, 2026
Oct 5, 2026Parisotto Shannon MCEVP, Disc & Safety Assessmentoption exercise981$208.44$204K5,788Oct 7, 2026
Oct 5, 2026Parisotto Shannon MCEVP, Disc & Safety Assessmentopen-market sale10b5-1981$308.44$303K4,807Oct 7, 2026
Sep 30, 2026Coleman GlennEVP & Chief Financial Officeropen-market buy10$297.43$3K27,762Oct 2, 2026
Aug 25, 2026Foster James CDirectoroption exercise21,132$194.12$4M52,728Aug 27, 2026
Aug 25, 2026Foster James CDirectoroption exercise12,429$208.44$3M65,157Aug 27, 2026
Aug 25, 2026Foster James CDirectoropen-market sale10b5-133,561$300.00$10M31,596Aug 27, 2026
Aug 19, 2026Girshick BirgitChief Executive Officer, Directorgift528$0.00—35,485Aug 20, 2026
Aug 19, 2026Parisotto Shannon MCEVP, Disc & Safety Assessmentoption exercise2,039$194.12$396K6,846Aug 20, 2026
Aug 19, 2026Parisotto Shannon MCEVP, Disc & Safety Assessmentopen-market sale10b5-12,039$294.12$600K4,807Aug 20, 2026
Aug 18, 2026Andrews Nancy CDirectoroption exercise573$164.30$94K2,011Aug 20, 2026
Aug 18, 2026Andrews Nancy CDirectoropen-market sale573$285.24$163K1,438Aug 20, 2026
Aug 11, 2026Girshick BirgitChief Executive Officer, Directoroption exercise6,500$179.66$1M42,513Aug 13, 2026
Aug 11, 2026Girshick BirgitChief Executive Officer, Directoropen-market sale10b5-16,500$279.90$2M36,013Aug 13, 2026
Aug 11, 2026Parisotto Shannon MCEVP, Disc & Safety Assessmentoption exercise3,714$179.66$667K8,521Aug 13, 2026
Aug 11, 2026Parisotto Shannon MCEVP, Disc & Safety Assessmentopen-market sale10b5-13,714$279.66$1M4,807Aug 13, 2026
Aug 10, 2026LaPlume Joseph WEVP, Corp Strategy & Developgift257$0.00—31,041Aug 11, 2026
Aug 10, 2026Foster James CDirectoroption exercise28,733$179.66$5M60,329Aug 11, 2026
Aug 10, 2026Foster James CDirectoropen-market sale10b5-128,733$275.00$8M31,596Aug 11, 2026
Aug 6, 2026Knell Michael GunnarSVP, Finance and CAOopen-market sale1,274$259.07$330K14,878Aug 10, 2026
Aug 6, 2026Knell Michael GunnarSVP, Finance and CAOopen-market sale901$260.63$235K13,977Aug 10, 2026
Aug 6, 2026Knell Michael GunnarSVP, Finance and CAOopen-market sale810$261.45$212K13,167Aug 10, 2026

Full insider history for Charles River Laboratories International, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC., CIK 1100682 on EDGAR
Extract generated
November 4, 2026
Withheld
none
Repaired
4 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2010, other income FY2010, net income FY2024, operating income FY2025
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/CRL.json